News & analysis

Vaccine rollout continues in March for its third month now, but significant obstacles still stand in its way. Since our February chartbook, increased supply plans by the single-shot drug of Johnson & Johnson have improved prospects for the global campaign, with the pharmaceutical company expanding delivery plans by 0.6 billion doses. Overall, the joint effort by the ten leading suppliers can now cover the entire world population’s treatment this year, but the devil is still in the distribution.  While delivery gaps have started to narrow across major economies, the race continues to show the UK and the US as the front runners in the G10 space, whereas Europe, Canada and Asian countries lag significantly. Moreover, prospects for developing economies are yet to improve. The pace of vaccination still sets the tone for market sentiment across the world, with currencies continuing to trade in line with main developments in the vaccination front. This dynamic competes with stimulus measures currently dominating the global outlook for growth and inflation in the medium-run, forcing central banks to manage policy expectations on the sidelines.




DISCLAIMER: This information has been prepared by Monex Canada Inc., an execution-only service provider. The material is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is, or should be considered to be, financial, investment or other advice on which reliance should be placed. No representation or warranty is given as to the accuracy or completeness of this information. No opinion given in the material constitutes a recommendation by Monex Canada Inc., or the author that any particular transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research, it is not subject to any prohibition on dealing ahead of the dissemination of investment research and as such is considered to be a marketing communication.